<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318016</url>
  </required_header>
  <id_info>
    <org_study_id>17-0754.cc</org_study_id>
    <nct_id>NCT03318016</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Trial of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the maximum tolerated dose (MTD) and toxicity profile of the combination of&#xD;
      cyclophosphamide and ATO (Arsenic Trioxide) in subjects with relapsed refractory AML.&#xD;
&#xD;
      Determine the efficacy of ATO and cyclophosphamide in this population, as defined by response&#xD;
      rate, response duration, event-free survival (EFS) and overall survival (OS).&#xD;
&#xD;
      Determine the number of transplant-eligible subjects who are successfully bridged to stem&#xD;
      cell transplantation or donor lymphocyte infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label phase 1 study of fixed dose ATO (Arsenic Trioxide) and escalating doses&#xD;
      of cyclophosphamide using a standard 3+3 dose escalation design. All subjects will be treated&#xD;
      with sequential cycles of 3 days of ATO at 0.15 mg/kg/d IV followed by Cyclophosphamide as a&#xD;
      single IV dose on day 4 along with mesna at a dose equal to the cyclophosphamide (for doses&#xD;
      ≥1000 mg/m2) and hydration for a maximum of 6 cycles. ATO and Cyclophosphamide will be&#xD;
      repeated every 28-42 days. Treatment will be given inpatient for the first cycle, with the&#xD;
      option of outpatient treatment for subsequent cycles. Subjects may remain on study in the&#xD;
      absence of disease progression or unacceptable toxicity for a maximum six cycles. Toxicity&#xD;
      assessments will be performed continuously; DLT determination will be made based on adverse&#xD;
      events (AEs) that occur during cycle 1 (day 1-28). An expansion cohort of ten subjects at the&#xD;
      maximum tolerated dose will occur at the conclusion of dose escalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2&#xD;
Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2&#xD;
Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2&#xD;
Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2&#xD;
Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2&#xD;
ATO and Cyclophosphamide will be repeated every 28 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally Tolerated Dose (MTD) of Cyclophosphamide and ATO</measure>
    <time_frame>6 months</time_frame>
    <description>MTD is defined as the highest dose level with no more than 1 DLT reported out of 6 DLT-evaluable subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) using ATO and Cyclophosphamide</measure>
    <time_frame>minimum 5 years</time_frame>
    <description>ORR defined by complete remission/complete remission with incomplete recovery of blood counts (CR/CRi), morphologic leukemia free state (MLFS) and partial responses (PR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Relapsed/Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort -1: Cyclophosphamide 500 mg/m2&#xD;
Cohort 1: Cyclophosphamide 1000 mg/m2&#xD;
Cohort 2: Cyclophosphamide 2000 mg/m2&#xD;
Cohort 3: Cyclophosphamide 3000 mg/m2&#xD;
Cohort 4: Cyclophosphamide 4000 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV dose along with Mesna (in subjects receiving &gt;1000mg/m2 Cy) and hydration for a maximum of 6 doses in the following dose escalation schema:&#xD;
Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2&#xD;
Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2&#xD;
Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2&#xD;
Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2&#xD;
Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. WHO-confirmed AML, other than APL, with no standard treatment options available&#xD;
&#xD;
          2. Age 18 years or older&#xD;
&#xD;
          3. Relapsed or refractory (resistant) disease, as defined by standard criteria7&#xD;
&#xD;
               -  Relapsed: Bone marrow blasts ≥5%, reappearance of blasts in the blood, or&#xD;
                  development of extramedullary disease following achievement of CR/CRi/CRp/MLFS&#xD;
&#xD;
               -  Refractory (resistant): Failure to achieve CR/CRi/MLFS in subjects who survive ≥7&#xD;
                  days following completion of initial treatment, with evidence of persistent&#xD;
                  leukemia by blood and/or bone marrow examination&#xD;
&#xD;
          4. &gt;14 days since any prior therapy for AML excluding hydroxyurea&#xD;
&#xD;
          5. Willing and able to understand and voluntarily sign a written informed consent&#xD;
&#xD;
          6. Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          7. Women of childbearing potential must use an acceptable form of birth control for 28&#xD;
             days prior to beginning study treatment, through the duration of study treatment, and&#xD;
             for 3 months after discontinuing study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class III or IV heart failure&#xD;
&#xD;
          2. Unstable angina pectoris&#xD;
&#xD;
          3. Significant uncontrolled cardiac arrhythmias, including ventricular arrhythmias,&#xD;
             congenital long QT syndrome, symptomatic atrial fibrillation, symptomatic bradycardia,&#xD;
             right bundle branch block plus left anterior hemiblock or bifasicular block&#xD;
&#xD;
          4. QTc &gt;500 ms, uncorrectable by managing electrolytes and medications, using the QTcF&#xD;
             formula in Appendix D.&#xD;
&#xD;
          5. Active acute graft vs. host disease ≥ grade 2 or active extensive chronic GVHD&#xD;
&#xD;
          6. Relapse after allogeneic stem cell transplantation prior to post-transplant day 30&#xD;
&#xD;
          7. Active central nervous system (CNS) involvement of leukemia (lumbar puncture not&#xD;
             required to rule out CNS involvement if not suspected)&#xD;
&#xD;
          8. Uncontrolled psychiatric illness that would limit compliance with requirements&#xD;
&#xD;
          9. Pregnant or breast feeding females&#xD;
&#xD;
         10. Laboratory abnormalities:&#xD;
&#xD;
               1. Either creatinine &gt;2.0 mg/dL or creatinine clearance &lt;30 mL/min&#xD;
&#xD;
               2. Total bilirubin &gt; 3 x institutional upper limit of normal (ULN) (unless&#xD;
                  documented Gilbert's syndrome)&#xD;
&#xD;
               3. AST or ALT &gt; 3 x institutional ULN, unless felt to be due to disease involvement&#xD;
&#xD;
         11. Other medical or psychiatric illness or organ dysfunction or laboratory abnormality&#xD;
             which, in the opinion of the investigator, would compromise the subject's safety or&#xD;
             interfere with data interpretation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Pollyea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

